ArticleAnnals of clinical and translational neurology2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.
Article in Annals of clinical and translational neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 383 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
383 citing papers in PubMed, 3 syntheses or guidelines pooled it, 651 citations in OpenAlex.
- Gene-based association analysis of depression risk among European ancestry Parkinson's disease patients.Human genetics · 2026Pooled it
- Glymphatic Dysfunction in Parkinson's Disease: A Systematic Review and Meta-Analysis of Neuroimaging Studies.Movement disorders clinical practice · 2026Pooled it
- Relationships between physical activities performed under free-living conditions and non-motor symptoms in people with Parkinson's: A systematic review and meta-analysis.Clinical rehabilitation · 2024Pooled it
- Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.Nature medicine · 2024Trial
- Altered static and dynamic functional network connectivity in Parkinson's disease: A multisite functional magnetic resonance imaging study.IBRO neuroscience reports · 2026Article
- Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact.Annals of clinical and translational neurology · 2026Article
- FA-MFMR: a multivariable functional Mendelian randomization method that accounts for correlated longitudinal exposures via factor augmentation.Bioinformatics (Oxford, England) · 2026Article
- A Variational Mean-Field Control Framework for Graph Representation Learning.IEEE transactions on pattern analysis and machine intelligence · 2026Article
- Baseline peripheral inflammatory profiles predict phenoconversion in prodromal Parkinson's disease: a longitudinal cohort study.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Article
- Lesion-Level Subtypes of White Matter Hyperintensity Evolution Beyond Spatial Location.Neurology · 2026Observational
- Equivocal Dopamine Transporter Imaging: Integrating Visual Assessment, Quantification, and Clinical Follow-Up.Life (Basel, Switzerland) · 2026Review
- Mapping the dual functional organization of the substantia nigra.Molecular psychiatry · 2026Article
- Exploring cerebral small vessel disease signatures in familial Parkinson's disease.Scientific reports · 2026Article
- Global research synergy: Advancing fundamental Parkinson's research through international collaboration.Journal of Parkinson's disease · 2026Review
- The effects of use of medications on striatal dopamine transporter binding assessed by [European journal of nuclear medicine and molecular imaging · 2026Article
- Peripheral blood transcriptomic signature is associated with cognitive impairment and freezing of gait in Parkinson's disease: a data-driven approach.NPJ Parkinson's disease · 2026Article
- Morphometric Explanations for Deep Learning Based Neuroimaging Classifiers.Human brain mapping · 2026Article
- Associations of epigenetic age acceleration with motor impairment: Evidence from the Parkinson's Progression Markers Initiative cohort.Neurobiology of aging · 2026Article
- Health system learning enables generalist neuroimaging models.Nature medicine · 2026Article
- Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α-Synuclein and Mediation of Age Effects.Movement disorders clinical practice · 2026Article
323 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 13 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker-defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease (PD) progression markers to accelerate disease-modifying therapeutic trials.
methodsA total of 423 untreated PD, 196 Healthy Control (HC) and 64 SWEDD (scans without evidence of dopaminergic deficit) subjects were enrolled at 24 sites. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.
resultsApproximately 9% of enrolled subjects had a single PD sign at baseline. DAT imaging excluded 16% of potential PD subjects with SWEDD. The total MDS-UPDRS for PD was 32.4 compared to 4.6 for HC and 28.2 for SWEDD. On average, PD subjects demonstrated 45% and 68% reduction in mean striatal and contralateral putamen Specific Binding Ratios (SBR), respectively. Cerebrospinal fluid (CSF) was acquired from >97% of all subjects. CSF (PD/HC/SWEDD pg/mL) α-synuclein (1845/2204/2141) was reduced in PD vs HC or SWEDD (
interpretationPPMI has detailed the biomarker signature for an early PD cohort defined by clinical features and imaging biomarkers. This strategy provides the framework to establish biomarker cohorts and to define longitudinal progression biomarkers to support future PD treatment trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.